BACKGROUND: In this study we have validated the feasibility of detecting disseminated tumor cells (DTC) by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Bone marrow samples from a large cohort of patients with breast cancer were analyzed for the presence of DTC by immunocytochemistry (ICC) or a molecular-based method. PATIENTS AND METHODS: Bone marrow samples were collected from 170 patients with breast cancer with stage I-IV disease before the initiation of any local or systemic treatment. Staining for cytokeratin (CK)-positive cells was performed with the Epimet kit. Disseminated tumor cells were also quantified by measuring relative gene expression for CK19 and mammaglobin (MAM) using a quantitative RT-PCR detection method. The mean follow-up time was 30 months. Kaplan-Meier analysis was used for predicting overall survival. RESULTS: Despite an excellent quantitative correlation and qualitative concordance between ICC and RT-PCR, survival analysis suggested an improved prognostic significance of DTC as detected by quantitative RT-PCR. Univariate survival analysis computed a relative risk of death of 2.87 for women with ICC-positive cells in the bone marrow, as compared with those without positive cells. The relative risk for women with RT-PCR-positive bone marrow was even higher: 3.5 (CK19) and 3.39 (MAM). In multivariate analysis, bone marrow CK19 was a stronger prognostic factor than bone marrow ICC. CONCLUSION: Reverse-transcriptase polymerase chain reaction-detected DTC is shown to be prognostically significant in untreated patients with breast cancer. Furthermore, it seems to be a more sensitive method for detecting DTC in bone marrow samples when compared with ICC.
BACKGROUND: In this study we have validated the feasibility of detecting disseminated tumor cells (DTC) by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Bone marrow samples from a large cohort of patients with breast cancer were analyzed for the presence of DTC by immunocytochemistry (ICC) or a molecular-based method. PATIENTS AND METHODS: Bone marrow samples were collected from 170 patients with breast cancer with stage I-IV disease before the initiation of any local or systemic treatment. Staining for cytokeratin (CK)-positive cells was performed with the Epimet kit. Disseminated tumor cells were also quantified by measuring relative gene expression for CK19 and mammaglobin (MAM) using a quantitative RT-PCR detection method. The mean follow-up time was 30 months. Kaplan-Meier analysis was used for predicting overall survival. RESULTS: Despite an excellent quantitative correlation and qualitative concordance between ICC and RT-PCR, survival analysis suggested an improved prognostic significance of DTC as detected by quantitative RT-PCR. Univariate survival analysis computed a relative risk of death of 2.87 for women with ICC-positive cells in the bone marrow, as compared with those without positive cells. The relative risk for women with RT-PCR-positive bone marrow was even higher: 3.5 (CK19) and 3.39 (MAM). In multivariate analysis, bone marrow CK19 was a stronger prognostic factor than bone marrow ICC. CONCLUSION: Reverse-transcriptase polymerase chain reaction-detected DTC is shown to be prognostically significant in untreated patients with breast cancer. Furthermore, it seems to be a more sensitive method for detecting DTC in bone marrow samples when compared with ICC.
Authors: Christian Schindlbeck; Ulrich Andergassen; Simone Hofmann; Julia Jückstock; Udo Jeschke; Harald Sommer; Klaus Friese; Wolfgang Janni; Brigitte Rack Journal: J Cancer Res Clin Oncol Date: 2013-03-23 Impact factor: 4.553
Authors: Chidananda M Siddappa; Mark A Watson; Sreeraj G Pillai; Kathryn Trinkaus; Timothy Fleming; Rebecca Aft Journal: Breast Cancer Res Treat Date: 2012-11-06 Impact factor: 4.872
Authors: C Matuschek; Edwin Bölke; G Lammering; P A Gerber; M Peiper; W Budach; H Taskin; H B Prisack; G Schieren; K Orth; H Bojar Journal: Eur J Med Res Date: 2010 Impact factor: 2.175
Authors: Annamaria Molino; Monica Giovannini; Rocco Micciolo; Alessandra Auriemma; Elena Fiorio; Antonio Santo; Gian Luigi Cetto Journal: Clin Med Oncol Date: 2008-09-04
Authors: R E Payne; N L Hava; K Page; K Blighe; B Ward; M Slade; J Brown; D S Guttery; S A A Zaidi; J Stebbing; J Jacob; E Yagüe; J A Shaw; R C Coombes Journal: Br J Cancer Date: 2011-12-13 Impact factor: 7.640
Authors: I Van der Auwera; D Peeters; I H Benoy; H J Elst; S J Van Laere; A Prové; H Maes; P Huget; P van Dam; P B Vermeulen; L Y Dirix Journal: Br J Cancer Date: 2009-12-01 Impact factor: 7.640
Authors: I Van der Auwera; H J Elst; S J Van Laere; H Maes; P Huget; P van Dam; E A Van Marck; P B Vermeulen; L Y Dirix Journal: Br J Cancer Date: 2009-04-21 Impact factor: 7.640